Skip to content Skip to sidebar Skip to footer
Chemist Warehouse is now ASX listed
Chemist Warehouse is now ASX listed! Here are 5 critical things all investors need to know!
Chemist Warehouse is now ASX listed - 14 months since the plan to list was first unveiled. Australia's largest pharmacy chain had long been mulled as an IPO candidate. But - with IPO conditions less than ideal - it chose to list via a reverse takeover of Sigma Healthcare (ASX:SIG). The irony is that despite…
TeamInvest Private
Teaminvest Private (ASX:TIP): The ASX’s most unique investment company!
Teaminvest Private (ASX:TIP) may not be as prominent an investment company as Magellan or Wilson, but perhaps it has not been getting the attention it deserves.Originating roughly 2 decades ago as an informal club of business owners for investment education and stock-picking purposes, it has evolved into a company with $1.6bn in funds in its…
Kinara
Here’s why the US$307m acquisition of Edge AI chip maker Kinara is big news for Nanoveu (ASX:NVU)
Edge AI chip maker Kinara is being bought by NXP Semiconductors (NASDAQ:NXPI) for US$307m, or nearly A$500m. NXP, a Dutch semiconductor manufacturer that is US listed and capped at over US$50bn, announced the all-cash purchase earlier this week. We think this is good news for ASX companies working on Edge AI chips, like Nanoveu (ASX:NVU).  Why…
Huntly Power Station
Here’s why the Huntly Power Station is being looked at…by Four ASX-listed energy companies
Its not every day you see four industry oligopolists publicly announcing they're eyeing off a single commercial asset, let alone working together to see if it could be viable, but that's what is happening with the Huntly Power Station.  Huntly Power Station: The largest such facility in New Zealand Huntly has been producing energy (mostly via…
Research and Development Tax Incentive
Here’s how Australia’s Research and Development Tax Incentive Works
Australia's Research and Development Tax Incentive (R&D Tax Incentive) regime can be useful for pre-commercialisation companies serving as a non-dilutive source of funding.Progressing new medical treatments or technologies to market is not a cheap exercise and it can be difficult to secure funding from investors (either debt or equity). Even if a company can secure…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here